Abstract
Background, The etiology of multiple sclerosis is unclear and infectious agents have been considered. Borrelia infections can cause an intrathecal inflammatory response with accompanying cerebral and spinal imaging findings.
 Cases. Two children with acute or subacute initial neurological presentation, subsequent relapsing course, and MR imaging features suggestive of multiple sclerosis are presented. A history of tick bite or dramatic response to antibiotic treatment supported Lyme disease in the beginning, but requirement of disaese-modifying treatment later in the course supported multiple sclerosis.
 Results. These cases carrying features supportive of both multiple sclerosis and Lyme disease caused clinical dilemma and were treated for both disorders. Borrelia-specific IgG index testing before any treatment could have prevented the difficulty in differential diagnosis.
 Conclusions. Clinical, imaging and CSF findings of multiple sclerosis and acute or chronic progressive borrelia encephalomyelitis may overlap and testing for Borrelia-specific intrathecal antibody synthesis should not be omitted in endemic areas.
Highlights
The etiology of multiple sclerosis is heterogeneous and resulting from a complex genetic and environmental interaction, so that infectious agents have been considered
These cases, which have features supportive of both multiple sclerosis and neuroborreliosis, caused clinical dilemma and the children were treated for both disorders
We present two cases which illustrate the overlap between pediatric Multiple sclerosis (MS) and Lyme neuroborreliosis by their subacute and relapsing neurological symptoms, imaging findings and response to treatment
Summary
The etiology of multiple sclerosis is heterogeneous and resulting from a complex genetic and environmental interaction, so that infectious agents have been considered. We present two cases which illustrate the overlap between pediatric MS and Lyme neuroborreliosis by their subacute and relapsing neurological symptoms, imaging findings and response to treatment. The relapse occurred at the age of 16 years and after recovery the patient was started on treatment with Beta-interferon 1a, 30 mg, once a week.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of the International Child Neurology Association
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.